Dostarlimab in advanced/recurrent (A/R) mismatch repair deficient/microsatellite instability-high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): the GARNET study

被引：0
|
作者：
Oaknin, Ana [1 ]
Pothuri, Bhavana [2 ,3 ]
Gilbert, Lucy [4 ]
Sabatier, Renaud [5 ]
Ghamande, Sharad [6 ]
Gravina, Adriano [7 ]
Calvo, Emiliano [8 ]
Banerjee, Susana [9 ,10 ]
Mangan, Niamh [11 ]
Miller, Rowan E. [12 ]
Pikiel, Joanna [13 ]
Mirza, Mansoor R. [14 ]
Duan, Tao [15 ]
Zildjian, Sybil [16 ]
Zografos, Eleftherios [17 ]
Veneris, Jennifer [16 ]
Tinker, Anna V. [18 ]
机构：
[1] Hosp Univ Vall dHebron, Gynaecol Canc Programme, Vall dHebron Inst Oncol VHIO, Vall dHebron Barcelona Hosp Campus, Barcelona, Spain
[2] NYU Langone Hlth, Gynecol Oncol Grp GOG, New York, NY USA
[3] NYU Langone Hlth, Dept Obstet Gynecol, Laura & Isaac Perlmutter Canc Ctr, New York, NY USA
[4] McGill Univ, Div Gynecol Oncol, Hlth Ctr, Montreal, PQ, Canada
[5] Aix Marseille Univ, Dept Med Oncol, Marseille, France
[6] Augusta Univ, Dept Obstet & Gynecol, Georgia Canc Ctr, Augusta, GA USA
[7] Ist Nazl Tumouri Fdn G Pascale, Clin Trial Unit, Naples, Italy
[8] Ctr Integral Oncol Clara Campal, START Madrid CIOCC, Madrid, Spain
[9] Royal Marsden NHS Fdn Trust, London, England
[10] Inst Canc Res, London, England
[11] GSK, Melbourne, Australia
[12] UCL, St Bartholomews Hosp London, London, England
[13] Reg Ctr Oncol, Dept Chemotherapy, Gdansk, Poland
[14] Rigshosp, Copenhagen Univ Hosp, Nord Soc Gynaecol Oncol Clin Trial Unit, Dept Oncol, Copenhagen, Denmark
[15] GSK, Pennington, NJ USA
[16] GSK, Waltham, MA USA
[17] GSK, London, England
[18] Univ British Columbia, Dept Med, British Columbia Canc, Vancouver Ctr, Vancouver, BC, Canada
来源：
ASIA-PACIFIC JOURNAL OF CLINICAL ONCOLOGY | 2022年 / 18卷
基金：
芬兰科学院;
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
218
引用
收藏
页码：133 / 134
页数：2
相关论文
共 50 条
  • [1] Dostarlimab in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability-high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC): The GARNET study.
    Oaknin, Ana
    Pothuri, Bhavana
    Gilbert, Lucy
    Sabatier, Renaud
    Ghamande, Sharad A.
    Gravina, Adriano
    Calvo, Emiliano
    Banerjee, Susana N.
    Miller, Rowan
    Pikiel, Joanna
    Mirza, Mansoor Raza
    Duan, Tao
    Zildjian, Sybil
    Zografos, Eleftherios
    Veneris, Jennifer Taylor
    Tinker, Anna
    Powell, Matthew A.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [2] Progression-free survival (PFS) and overall survival (OS) in advanced/recurrent (AR) mismatch repair deficient/microsatellite instability-high or proficient/stable (dMMR/MSI-H or MMRp/MSS) endometrial cancer (EC) treated with dostarlimab in the GARNET study
    Tinker, A. V.
    Pothuri, B.
    Gilbert, L.
    Sabatier, R.
    Brown, J.
    Ghamande, S.
    Mathews, C.
    O'Malley, D.
    Boni, V.
    Gravina, A.
    Banerjee, S.
    Miller, R.
    Pikiel, J.
    Mirza, M. R.
    Duan, T.
    Antony, G.
    Zildjian, S.
    Zografos, E.
    Veneris, J.
    Oaknin, A.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S798 - S799
  • [3] Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET - a phase I, single-arm study
    Oaknin, Ana
    Gilbert, Lucy
    Tinker, Anna, V
    Brown, Jubilee
    Mathews, Cara
    Press, Joshua
    Sabatier, Renaud
    O'Malley, David M.
    Samouelian, Vanessa
    Boni, Valentina
    Duska, Linda
    Ghamande, Sharad
    Ghatage, Prafull
    Kristeleit, Rebecca
    Leath, Charles, III
    Guo, Wei
    Im, Ellie
    Zildjian, Sybil
    Han, Xinwei
    Duan, Tao
    Veneris, Jennifer
    Pothuri, Bhavana
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 (01)
  • [4] Interim analysis of the immune-related endpoints of the mismatch repair deficient/microsatellite instability high (dMMR/MSI-H) and proficient/stable (MMRp/MSS) endometrial cancer cohorts from the GARNET study
    Hanker, L.
    Oaknin, A.
    Gilbert, L.
    Tinker, A., V
    Sabatier, R.
    Boni, V
    O'Malley, D.
    Ghamande, S.
    Duska, L.
    Ghatage, P.
    Sullivan, R. J.
    Moreno, V
    Veneris, J.
    Duan, T.
    Im, E.
    Pothuri, B.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 239 - 240
  • [5] DOSTARLIMAB IN ADVANCED/RECURRENT MISMATCH REPAIR DEFICIENT/MICROSATELLITE INSTABILITY HIGH OR PROFICIENT/STABLE ENDOMETRIAL CANCER: THE GARNET STUDY
    Oaknin, A.
    Gilbert, L.
    Tinker, A. V.
    Brown, J.
    Mathews, C.
    Press, J.
    Sabatier, R.
    O'malley, D. M.
    Samouelian, V.
    Boni, V.
    Duska, L.
    Ghamande, S.
    Ghatage, P.
    Kristeleit, R.
    Leath, C.
    Veneris, J.
    Duan, T.
    Im, E.
    Pothuri, B.
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2021, 31 : A85 - A86
  • [6] PATIENT-REPORTED OUTCOMES (PROS) IN THE GARNET TRIAL IN PATIENTS (PTS) WITH ADVANCED OR RECURRENT MISMATCH REPAIR DEFICIENT/MICROSATELITE INSTABILITY-HIGH (DMMR/MSI-H) ENDOMETRIAL CANCER (EC) TREATED WITH DOSTARLIMAB
    Kristeleit, Rebecca
    Mathews, Cara
    Redondo, Andres
    Huang, Joice
    Eliason, Laurie
    Im, Ellie
    Brown, Jubilee
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A40 - A41
  • [7] Patient-reported outcomes (PROs) in the GARNET trial in patients (pts) with advanced or recurrent mismatch repair deficient/microsatelite instability-high (dMMR/MSI-H) endometrial cancer (EC) treated with dostarlimab
    Kristeleit, R.
    Matthews, C.
    Redondo, A.
    Huang, J.
    Eliason, L.
    Im, E.
    Brown, J.
    ANNALS OF ONCOLOGY, 2020, 31 : S637 - S637
  • [8] SAFETY AND ANTITUMOR ACTIVITY OF DOSTARLIMAB IN PATIENTS (PTS) WITH ADVANCED OR RECURRENT DNA MISMATCH REPAIR DEFICIENT (DMMR) OR PROFICIENT (MMRP) ENDOMETRIAL CANCER (EC): RESULTS FROM THE GARNET STUDY
    Oaknin, Ana
    Gilbert, Lucy
    Tinker, Anna V.
    Sabatier, Renaud
    Boni, Valentina
    O'malley, David M.
    Ghamande, Sharad
    Guo, Wei
    Im, Ellie
    Pothuri, Bhavana
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2020, 30 : A39 - A40
  • [9] Safety and antitumor activity of dostarlimab in patients (pts) with advanced or recurrent DNA mismatch repair deficient (dMMR) or proficient (MMRp) endometrial cancer (EC): Results from GARNET
    Oaknin, A.
    Gilbert, L.
    Tinker, A. V.
    Sabatier, R.
    Boni, V.
    O'Malley, D. M.
    Ghamande, S.
    Duska, L.
    Ghatage, P.
    Guo, W.
    Im, E.
    Pothuri, B.
    ANNALS OF ONCOLOGY, 2020, 31 : S1166 - S1166
  • [10] Primary analysis of GEICO 120/DORA, a real-world multicentre study of dostarlimab in patients with recurrent or advanced DNA mismatch repair deficient/microsatellite instability-high (DMMR/MSI-H) endometrial cancer
    Gallego, Alejandro
    Madariaga, Ainhoa
    Estevez-Garcia, Purificacion
    Alberti, Facundo
    Carbo, Anna
    Palacio, Isabel
    Churruca, Cristina
    Galvez, Fernando
    Ortega, M. Eugenia
    Murata, Paola
    Manzano, Aranzazu
    Masvidal, Maria
    Martin-Lorente, Cristina
    Hernando, Blanca
    Lozano, Inmaculada
    Cueva, Juan F.
    Garcia-Illescas, David
    Falco, Esther
    Mendiola, Marta
    Redondo, Andres
    INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2024, 34 (SUPPL_1) : A182 - A182
12345